会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Particulate acellular tissue matrix
    • 颗粒无细胞组织基质
    • US20050159822A1
    • 2005-07-21
    • US11040127
    • 2005-01-20
    • Edward GriffeyStephen LiveseyCharles SchiffLawrence Boerboom
    • Edward GriffeyStephen LiveseyCharles SchiffLawrence Boerboom
    • A61K9/00A61K9/19A61K35/12A61K35/28A61K35/32A61K35/36A61K38/18A61K47/42A61L27/24A61L27/36A61L27/38A61L31/00A61F2/02
    • A61L27/3804A61K9/0024A61K9/19A61K35/28A61K35/32A61K35/36A61K38/18A61K47/42A61L27/24A61L27/3604A61L27/3683A61L31/005A61L2430/40Y10S514/801
    • A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acelluar tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.
    • 一种处理无细胞组织基质以产生颗粒状无细胞组织基质的方法包括:将干燥的无细胞组织基质的片材切成条带; 在低温下对干燥的无细胞组织基质条进行冷冻干燥; 将所得颗粒在低温下分离大小; 并冷冻干燥所需尺寸的颗粒级分以除去可能被吸收的任何水分,以产生干燥的无细胞组织基质。 干燥颗粒状无细胞组织基质的再水合可以在使用前进行。 颗粒状脱细胞组织可以通过注射,喷雾,分层,包装,套管或其组合施用于受体部位。 颗粒状细丝组织还可以包括生长和刺激剂,其选自表皮生长因子,成纤维细胞生长因子,神经生长因子,角质形成细胞生长因子,血小板衍生生长因子,血管活性肠肽,干细胞因子,骨形态蛋白,软骨细胞生长因子和 其组合。 其他药物活性化合物可以与再水合的颗粒材料组合,包括:止痛药; 止血药; 抗生素药物; 局部麻醉剂等,以增强植入颗粒物质的接受性。 颗粒材料产品还可以与选自间充质干细胞,表皮干细胞,软骨干细胞,造血干细胞及其组合的干细胞组合。
    • 3. 发明申请
    • Particulate Acellular Tissue Matrix
    • 颗粒无细胞组织矩阵
    • US20070078522A2
    • 2007-04-05
    • US11040127
    • 2005-01-20
    • Edward GriffeyStephen LiveseyCharles SchiffLawrence Boerboom
    • Edward GriffeyStephen LiveseyCharles SchiffLawrence Boerboom
    • A61F2/02
    • A61L27/3804A61K9/0024A61K9/19A61K35/28A61K35/32A61K35/36A61K38/18A61K47/42A61L27/24A61L27/3604A61L27/3683A61L31/005A61L2430/40Y10S514/801
    • A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acellular tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.
    • 一种处理无细胞组织基质以产生颗粒状无细胞组织基质的方法包括:将干燥的无细胞组织基质的片材切成条带; 在低温下对干燥的无细胞组织基质条进行冷冻干燥; 将所得颗粒在低温下分离大小; 并冷冻干燥所需尺寸的颗粒级分以除去可能被吸收的任何水分,以产生干燥的无细胞组织基质。 干燥颗粒状无细胞组织基质的再水合可以在使用前进行。 颗粒状脱细胞组织可以通过注射,喷雾,分层,包装,套管或其组合施用于受体部位。 颗粒细胞组织还可以包括生长和刺激剂,其选自表皮生长因子,成纤维细胞生长因子,神经生长因子,角质形成细胞生长因子,血小板衍生生长因子,血管活性肠肽,干细胞因子,骨形态蛋白,软骨细胞生长因子和 其组合。 其他药物活性化合物可以与再水合的颗粒材料组合,包括:止痛药; 止血药; 抗生素药物; 局部麻醉剂等,以增强植入颗粒物质的接受性。 颗粒材料产品还可以与选自间充质干细胞,表皮干细胞,软骨干细胞,造血干细胞及其组合的干细胞组合。
    • 7. 发明申请
    • Cryopreservation of human red blood cells
    • 人类红细胞的冷冻保存
    • US20060127375A1
    • 2006-06-15
    • US11334950
    • 2006-01-18
    • Stephen LiveseyMichael BurnettJerome ConnorChristopher Wagner
    • Stephen LiveseyMichael BurnettJerome ConnorChristopher Wagner
    • A61K35/14A01N1/02A61K31/70A61K31/7048A61K31/522A61K31/7012
    • A01N1/02A01N1/0226A61K35/18
    • A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.
    • 红细胞储存组合物包括红细胞和生物化学改变试剂的组合物,所述生物化学改变试剂以浓度存在,以便将冻融循环期间的红细胞溶血百分比降低至百分比以下 在没有生物化学改变试剂的情况下红细胞溶血。 红细胞储存组合物优选包括选自以下的试剂:糖酵解/代谢组分的改性剂,抗氧化剂潜力的改性剂,细胞内离子分布的作用剂,膜流动性的调节剂,细胞骨架结构的改性剂,环加氧酶第二信使途径的作用者, 脂氧合酶第二信使通路,己糖单磷酸第二信使途径的作用子,磷酸化第二信使途径的作用剂,特异信使分子的改性剂及其组合。